Variables | N (%) | Low NLR (%) | High NLR(%) | P-value |
---|---|---|---|---|
Gender | ||||
Female | 50 (25.1) | 35 (70.0) | 15 (30.0) | |
Male | 149 (74.9) | 98 (65.8) | 51 (34.2) | 0.583 |
Age, years | ||||
<60 | 135 (67.2) | 90 (66.7) | 45 (33.3) | |
≥60 | 64 (31.8) | 43 (67.2) | 21 (32.8) | 0.942 |
Tumor stage before CRT | ||||
II | 26 (13.1) | 23 (88.5) | 3 (11.5) | |
III | 173 (86.9) | 110 (63.6) | 63 (36.4) | 0.012 |
Tumor location | ||||
Low | 122 (61.3) | 82 (67.2) | 40 (32.8) | |
Middle-high | 77 (38.7) | 51 (66.2) | 26 (33.8) | 0.886 |
CEA, ng/ml | ||||
<5 | 110 (55.3) | 77 (70.0) | 33 (30.0) | |
≥5 | 89 (44.7) | 56 (62.9) | 33 (37.1) | 0.292 |
RT dose, Gy | ||||
45-50 | 122 (61.3) | 76 (62.3) | 46 (37.7) | |
>50 | 77 (38.7) | 57 (74.0) | 20 (26.0) | 0.087 |
Surgical procedure | ||||
APR | 115 (57.8) | 81 (70.4) | 34 (29.6) | |
LAR | 70 (35.2) | 45 (64.3) | 25 (35.7) | |
Hartmann | 14 (7.0) | 7 (50.0) | 7 (50.0) | 0.246* |
ypTNM staging | ||||
ypT0-2 N0 | 88 (44.2) | 62 (70.5) | 26 (29.5) | |
ypT3-4 or N+ | 111 (55.8) | 71 (64.0) | 40 (36.0) | 0.334 |
TRG score | ||||
0-1 | 117 (58.8) | 82 (70.1) | 35 (29.9) | |
2-3 | 82 (41.2) | 51 (62.2) | 31 (37.8) | 0.245 |
Adjuvant chemotherapy | ||||
Yes | 184 (92.5) | 121 (65.8) | 63 (34.2) | |
No | 15 (7.5) | 12 (80.0) | 3 (20.0) | 0.393* |